Narcolepsy: Genetic predisposition and neuropharmacological mechanisms

Sleep Medicine Reviews

Volumn 4, Issue 1, 2000, Pages 57-99

  Nishino, Seiji ^a   Okura, Mutsumi ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Hypochetin; Modafinil; Narcolepsy; Orexin; REM sleep; Stimulants

Indexed keywords

ANTIDEPRESSANT AGENT; CAFFEINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OREXIN; PAROXETINE; PROTRIPTYLINE; VENLAFAXINE; VILOXAZINE; ZIMELDINE;

CATAPLEXY; FAMILIAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC PREDISPOSITION; HUMAN; NARCOLEPSY; NEUROPHARMACOLOGY; PATHOPHYSIOLOGY; REM SLEEP; REVIEW; RISK FACTOR; SOMNOLENCE;

EID: 0034070166     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.1999.0069     Document Type: Review

References (173)

1. Gazette des Hôpitaux. 53:1880;626-628.
2. ICSD Chairman. International classification of sleep disorders. Diagnostic and coding manual. Diagnostic Classification Steering Committee, Thorpy MJ, Rochester, MN: American Sleep Disorders. 1990.
3. Riehl J, Choi S, Mignot E, Nishino S. Changes with age in severity of cataplexy and in sleep/wake fragmentation in narcoleptic Doberman pinschers. Sleep. 22(S):1999;S3.
4. Billiard M, Besset A, Cadilhac J. The clinical and polygraphic development of narcolepsy. In Guilleminault C, Lugaresi E (eds). Sleep/wake disorders: natural history, epidemiology and longterm evolution. New York: Raven Press. 1983;171-185.
5. Sonka K, Tafti M, Billiard M. Narcolepsy and ageing. In Smiru S, Frauceschi M, Ferini-Stambi L (eds). Sleep and Aging, Milano: Masson. 1991;181-186.
6. Guilleminault C. Narcolepsy Syndrome. In Kryger MH, Roth R, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W. B. Saunders Company. 1994;549-561.
7. Aldrich M. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology. 46:1996;393-401.
8. Hublin C, Kaprio J, Partinene M, Koskenvuo M, Heikkila K, Koskimies S. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol. 35:1994;709-716.
9. Tashiro T, Kambayashi T, Hishikawa Y. An epidemiological study of narcolepsy in Japanese. In: The 4th International Symposium on Narcolepsy; 1994; Tokyo, Japan. 13:1994.
10. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 50 (Suppl 1):1998;S16-S22.
11. Guilleminault C, Mignot E, Dement WC, Grumet FC. Familial patterns of narcolepsy. Lancet. 335:1989;1376-1379.
12. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 52:1997;27-78.
13. Baker T, Foutz A, Neyman V, Dement W. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol. 75:1982;729-742.
14. Mignot E, Wang C, Rattazzi C, Gaiser C, Lovtt M, Guilleminault C. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin μ chain switch-like segment. Proc Natl Acad Sci USA. 88:1991;3475-3478.
15. Cederberg R, Nishino S, Dement WC, Mignot E. The Stanford narcoleptic canine colony: twenty years of breeding history. Vet Rec. 142:1998;31-36.
16. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobermans. Exp Neurol. 152:1998;292-302.
17. Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of narcolepsy. J Neurosci. 15:1995;4806-4814.
18. Nishino S, Honda K, Riehl J, Okura M, Mignot E. Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans. Neuroreport. 9:1998;3653-3661.
19. Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E. Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in a canine model. J Neurosci. 16:1996;4588-4595.
20. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry. 169:1996;459-467.
21. Ondze B, Lubin S, Lavandier B, Kohler F, Mayeux D, Billiard M. Frequency of narcolepsy in the population of a French ««Department»» J Sleep Res. 7 (Suppl 2):1998;193.
22. Roth B. Narcolepsy and Hypersomnia. Basel: Karger. 1980.
23. Dement WC, Carskadon M, Ley R. The prevalence of narcolepsy II. Sleep Res. 2:1973;147.
24. Solomon P. Narcolepsy in Negroes. Dis Nerv Sys. 6:1945;179-183.
25. Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city. Sleep Res. 8:1979;191.
26. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep. 10:1987;608-609.
27. Westphal C. Eigenthümliche mit Einschläfen verbundene Anfälle. Arch Psychiat. 7:1877;631-635.
28. Billiard M, Pasquie-Magnetto V, Heckman M, Carlander B, Besset A, Zachariev Z. Family studies in narcolepsy. Sleep. 17(Suppl):1994;S54-S59.
29. Lankford DA, Wellman JJ, O'Hara C. Postraumatic narcolepsy in mild to moderate closed head injury. Sleep. 17:1994;S25-S28.
30. Orellana C, Villemin E, Tafti M, Carlander B, Beset A, Billiard M. Life events in the year preceding the onset of narcolepsy. Sleep. 17:1994;S50-S53.
31. Charron D. Molecular basis of human leukocyte antigen class II disease associations. Adv Immunol. 48:1990;107-159.
32. Honda Y, Doi Y, Juji T, Satake M. Positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr Neurol Jpn. 38:1984;360.
33. Matsuki K, Honda Y, Satake M, Juji T. HLA in Narcolepsy in Japan. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Springer-Verlag. 1988;58-75.
34. Langdon N, Welsh KI, Van Dam M, Vaughan RW, Parkes D. Genetic markers in Narcolepsy. Lancet. 2:1984;1178-1180.
35. Billiard M, Seignalet J, Besset A, Cadihac J. HLA-DR2 and narcolepsy. Sleep. 9:1986;149-152.
36. Neely S, Rosenberg R, Spire J, Antel J, Arnason B. HLA antigens in narcolepsy. Neurology. 37:1987;1858-1860.
37. Matsuki K, Grumet FC, Lin X, Guilleminault C, Dement WC. DQ rather than DR gene marks susceptibility to narcolepsy. Lancet. 339:1992;1052.
38. Honda Y, Matsuki K. Genetic aspects of narcolepsy. In Thropy M (ed). Handbook of sleep disorder. New York: Marcel Dekker, Inc. 1990;217-234.
39. Mueller-Eckardt G, Meier-Ewert K, Schendel D, Reinecker F, Multhoff G, Muller-Eckardt C. HLA and narcolepsy in a German population. Tissue Antigens. 28:1986;163-169.
40. Montplaisir J, Poirier G. HLA in Narcolepsy in Canada. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Springer-Verlag. 1988;97-107.
41. Roth B, Nevsimalova S, Sonka K, Docekal P, Schulz H, Geisler P. A study of occurrence of HLA DR2 in 124 narcoleptics: clinical aspects. Arch Suiss Neurol et de Psychiat. 139:1988;41-51.
42. Honda Y, Matsuki K. Genetic aspects of narcolepsy. In Thorpy M (ed). Handbook of sleep disorder. New York: Marcel Dekker, Inc. 1990;217-234.
43. Mignot E, Hayduk R, Grumet FC, Black J, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 20:1997;1012-1020.
44. Lin L, Kuwata S, Tokunaga K, Sasaki T, Honda Y, Juji T. Analysis of HLA class II genes by single-strand conformation polymorphisms in narcolepsy. In Tsuji K, Aizawa M, Sasasuki T (eds). HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. New York: Oxford University Press. 1992;333-335.
45. Kwon OJ, Peled N, Miller K, Pillar G, Peled R, Lavie P. HLA class II analysis in Jewish Israeli narcoleptic patients. Hum Immunol. 44:1995;199-202.
46. Fogdell A, Hillert J, Sachs C, Olerup O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens. 46:1995;333-336.
47. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmeyer J. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in caucasian and black Americans. Sleep. 17:1994;S60-S67.
48. Fernandez-vina M, Gao X, Moraes M, Moraes J, Salatiel I, Miller S. Alelles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics. 34:1991;299-312.
49. Fernandez-Vina M, Moraes JR, Moraes ME, Miller S, Stasny P. HLA class II haplotypes in Amerindians and in black North and South Americans. Tissue Antigens. 38:1991;235-237.
50. Lin L, Jin L, Kimura A, Carrington M, Mignot E. DQ microsatellite association studies in three ethnic groups. Tissue Antigens. 50:1997;507-520.
51. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol. 148:1992;249-258.
52. Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G. Extensive HLA Class II studies in 58 non DRB!*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens. 49:1997;329-341.
53. Ellis M, Hetisimer AH, Ruddy DA, Hansen SL, Kronmal GS, McClelland E. HLA class II haplotype and sequence analysis support a role of DQ in narcolepsy. Immunogenetics. 46:1997;410-417.
54. Pelin Z, Guilleminault C, Rish N, Grumet FC, Mignot E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens. 51:1998;96-100.
55. Mignot E, Young T, Lin L, Finn L, Palta M. Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. Lancet. 351:1998;727.
56. Schulz H, Geisler P, Pollmächer T, Andreas-Zietz A, Keller E, Scholz S. HLA-DR2 correlates with rapid-eye-movement sleep latency in normal human subjects. Lancet. 2:1986;803.
57. Mignot E, Kimura A, Latterman A, Lin X, Yasunaga S, Mueller-Eckardt G. Extensive HLA Class II studies in 58 non DRB1*15(DR2) narcoleptic patients with cataplexy. Tissue Antigens. 49:1997;329-341.
58. Mignot E, Lin X, Kalil J, George C, Singh S, Billiard M. DQB1-0602 (DQwl) is not present in most non-DR2 caucasian narcoleptics. Sleep. 15:1992;415-422.
59. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 50 (Suppl 1):1998;S16-S22.
60. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA Class II studies in 509 narcoleptic patients. Sleep Res. 26:1997;433.
61. Mignot E, Lin L, Risch N, Honda Y, Fernandez-Vina M, Juji T. Identification of a novel HLA narcolepsy susceptibility subtype, HLA-DQB1*0301. Sleep. 22:1999;S121.
62. Mignot E, Guilleminault C, Grumet FC, Dement WC. Is narcolepsy an autoimmune disease? In Smirne S, Francesci M, Ferini-Strambi L, Zucconi M (eds). Proceedings of the Third Milano International Symposium, September 18-19 ««Sleep, Hormones, and the Immune System»». Milan: Masson. 1992;29-38.
63. Frederickson S, Carlander B, Billiard M, Link H. CSF immune variable in patients with narcolepsy. Acta Neurol Scand. 81:1990;253-254.
64. Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Spinger-Verlag. 1988;150-157.
65. Mignot E, Nishino S, Hunt Sharp L, Arrigoni J, Siegel J, Reid M. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci. 13:1993;1057-1064.
66. Nishino S, Mignot E. Neurobiology of Narcolepsy. Neuroscientist. 4:1998;133-143.
67. Knecht CD, Oliver JE, Redding R, Selcer R, Johnson G. Narcolepsy in a dog and a cat. J Am Vet Med Assoc. 162:1973;1052-1053.
68. Mitler M, Boysen M, Campbell L, Dement W. Narcolepsy-cataplexy in a female dog. Exp Neurol. 45:1974;332-340.
69. Honda Y. Clinical features of narcolepsy. In Honda Y, Juji T (eds). HLA in narcolepsy. Berlin: Springer-Verlag. 1988;24-57.
70. Dean RR, Kilduff TS, Dement WC, Grumet FC. Narcolepsy without unique MHC class II antigen association: Studies in the canine model. Hum Immunol. 25:1989;27-35.
71. Dutra AS, Mignot E, Puck JM. Establishing FISH methodology to study synthetic regions between canine and human chromosomes. Am J Hum Genet. 57:1995;A112.
72. Faraco J, Lin X, Li R, Hinton L, Lin L, Mignot E. Genetic studies in narcolepsy, a disorder of REM sleep. J Heredity. 90:1999;129-132.
73. Li R, Mignot E, Faraco J, Kadotani H, Cantanese J, Zhao B. Construction and characterization of an eight fold redundant dog genomic bacterial artificial chromosome library. Genomics. 58:1999;9-17.
74. Roehrs T, Zorick FRW, Paxton C, Sicklesteel J, Roth T. Alerting effects of naps in patients with narcolepsy. Sleep. 9:1986;194-199.
75. Thorpy MJ, Goswami M. Treatment of narcolepsy. In Thorpy MJ (ed.). Handbook of Sleep Disorders. New York: Marcel Dekker, Inc. 1990;235-258.
76. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep. 16:1993;444-456.
77. Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nursing. 16:1984;326-334.
78. American Narcolepsy Association. Stimulant medication survey. The Eye Opener. 1992;1-3.
79. American Sleep Disorders Association. Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep. 17:1994;348-351.
80. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA. 105:1935;2051-2054.
81. Alles GA. The comparative physiological actions of d 1-beta-phenylisopropylamines: pressor effects and toxicity. J Pharmacol Exp Ther. 47:1933;339-354.
82. Parkes JD, Fenton GW. Levo(-)amphetamine and dextro(+)amphetamine in the treatment of narcolepsy. J Neurol Neurosurg Psychiatry. 36:1973;1076-1081.
83. Parkes D. Amphetamines and other drugs. In: Sleep and its disorders. London: W.B. Saunders Company. 1985;459-482.
84. Kanbayashi T, Nishino S, Honda K, Shelton J, Dement WC, Mignot E. Differential effects of D- and L-amphetamine isomers on dopaminergic transmission: Implication for the control of alertness in canine narcolepsy. Sleep Res. 26:1997;383.
85. Parkes JD. Amphetamines and alertness. In Guilleminault C, Dement WC, Passouant P (eds). Narcolepsy. New York: Spectrum publication. 1976;643-658.
86. Yoss RE, Daly DD. Treatment of narcolepsy with ritalin. Neurology. 9:1959;171-173.
87. Pawluk LK, Hurwitz TD, Schulter JL, Ullewig C, Mahowald MW. Psychiatric morbidity in narcoleptics on chronic high doses methylphenidate therapy. J Nerv Ment Dis. 183:1995;45-48.
88. Rogers AE, Aldrich MS, Rosenberg AM. Compliance with stimulant medications in patients with Narcolepsy. Sleep. 20:1996;28-33.
89. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep. 9:1986;265-268.
90. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online. 1:1998;49-61. http://www.sro.org/1998/Nishino/49/.
91. Miler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep. 17:1994;352-371.
92. Fujimori M, Himwich HE. Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. Int J Neuropharmac. 8:1969;601-613.
93. Seijun T. Metamphetamine psychosis. In Ellinwood EH, Cohen S (eds). Current Concept on Amphetamine Abuse. Rockville, Naryland: National Institute of Mental Health. 1970;159-161.
94. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiat. 12:1988;695-700.
95. Besset A, Tafti M, Villemine E, Billiard M. Effect du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique. Neurophysiol Clin. 23:1993;47-60.
96. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effect of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol. 16:1993;46-53.
97. US modafinil in narcolepsy multicenter study group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 43:1998;88-97.
98. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 49:1997;444-451.
99. Brougton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H. Modafinil for the treatment of excessive daytime sleepiness in narcolepsy: a double-blind, placebo-controlled, cross-over trial. Sleep Research. 26:1998;336.
100. Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys. In French Association des Pharmacologistes Tours; 1991. Fundam Clin Pharmacol. 1991;825.
101. Gold LH, Balster RH. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology. 126:1996;286-292.
102. Edgar DM, Seidel WF, Contreras P, Vaught JL, Dement WC. Modafinil promotes EEG wake without intensifying motor activity in the rat. Can J Physiol Pharmacol. 72:1994;S1:362.
103. Rall TR. Central nervous system stimulants. In Gilman AG, Goodman LS, Rall TW, Murad F (eds). The Pharmacological Basis of Therapeutics, 7th edn. New York: Pergamon Press. 1985;345-382.
104. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Sys. 21:1960;704-706.
105. Henry GK, Hart RP, Kwentus JA, Sicola MJ. Effects of protriptyline on vigilance and information processing in narcolepsy. Psychopharmacol. 95:1988;109-112.
106. Raynal D. Polygraphic aspects of narcolepsy. In Guillemault CWCD, Passouant P (eds). Narcolepsy. New York: Spectrum publications, Inc. 1976;669-684.
107. Baldessarini RJ. How do antidepressants work? In Davis JM, Mass JW (eds). The Affective Disorders. Washington, D.C.: American Psychiatric Press. 1983;243-260.
108. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 9:1986;371-373.
109. Montplaisir J, Godbout R. Serotonergic reuptake mechanisms in the control of cataplexy. Sleep. 9:1986;280-284.
110. Schrader H, Bendixen-Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 74:1986;297-303.
111. Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neuro Sci. 3:1965;453-461.
112. Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 9:1986;260-264.
113. Guilleminault C, Raynal D, Takahashi S, Carskdon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 54:1976;71-87.
114. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol. 32:1975;653-656.
115. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 16:1993;706-712.
116. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 43:1980;171-174.
117. Poceta JS, Hajdukovic R, Mitler MM. Improvement in cataplexy with yohimbine and paroxetine: case report. Sleep Res. 23:1994;304.
118. Guilleminault C, Mancuso J, Salva MAQ, Hayes B, Mitler M, Poirier G. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 9:1986;275-279.
119. Godbout R, Poirier G, Montplaisir J. New treatment for narcolepsy (viloxazine). In Burton SA, Dement WC, Ristanovic R (eds). Narcolepsy, 3rd International Symposium, 1988. San Diego. 1988;79-81.
120. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology. 113:1993;76-82.
121. Smith M, Parkes J, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 5 (Suppl 1):1996;217.
122. Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In Guilleminault C, Dement WC, Passouant P (eds). Narcolepsy. New York: Spectrum Publications. 1976;625-638.
123. Koran L, Raghavan S. Fluoxetine for isolated sleep paralysis. Psychomatics. 34:1993;184-187.
124. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with γ-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 9:1986;285-289.
125. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gammahydroxybutyrate in California. West J Med. 156:1992;380-384.
126. Bédard M, Jacques M, Godbout R, Lapierre O. Nocturnal γ-hydroxybutyrate. Clin Neuropharmacol. 12:1989;29-36.
127. Kaitin KI, Kilduff TS, Dement WC. Sleep fragmentation in genetically narcoleptic dogs. Sleep. 9:1986;116-119.
128. Nishino S, Reid M, Dement WC, Mignot E. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep. 17:1994;S84-S92.
129. Guilleminault C. Cataplexy. Narcolepsy (Advances in Sleep Research Vol. 3). 1976;125-143.
130. Siegel JM. Brainstem mechanisms generating REM sleep. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company. 1994;125-144.
131. Baker TL, Dement WC. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In McGinty DJ, Drucker-Colin R, Morrison A, Parmeggiani PL (eds). Brain Mechanisms of Sleep. New York: Raven Press. 1985;199-233.
132. Trulson ME, Jacobs BL. Raphe unit activity in freely moving cats: Correlation with level of behavioral arousal. Brain Res. 163:1979;135-150.
133. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1:1981;876-886.
134. Miller JD, Farber J, Gatz P, Roffwarg H, German DC. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 273:1983;133-141.
135. Trulson M, Preussler DW, Howell GA. Activity of substantia nigra units across the sleep-waking cycle in freely moving cats. Neurosci Lett. 26:1981;183-188.
136. Peet M, Coppen A. The pharmacokinetics of antidepressant drugs: relevance to their therapeutic effect. In Paykel ES, Coppen A (eds). Psychopharmacology of Affective Disorders. Oxford: Oxford University Press. 1979;91-107.
137. Schmidt H, Clark R, Hyman R. Protriptyline: an effective agent in the treatment of narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry. 134:1977;183-185.
138. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 7:1990;93-118.
139. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacology. 7 (Suppl 1):1997;S37-S47.
140. Fuller RW, Snoddy HD, Perry KW, Bymaster FP, Wong DT. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine. Biochem Pharmacol. 27:1977;193-198.
141. Ross SB. The central stimulatory action of inhibitors of dopamine uptake. Life Sci. 24:1979;159-168.
142. Sulser F, Mobley PL. Biochemical effects of antidepressants in animals. In Hoffmeister F, Stille G (eds). Psychotropic Agent: Antipsychotics and Antidepressants, Handbook of Experimental Pharmacology. Berlin: Springer-Verlag. 1980;471-490.
143. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther. 264:1993;1079-1084.
144. Nishino S, Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC. Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J Pharmacol Exp Ther. 253:1990;1145-1152.
145. Nishino S, Arrigoni J, Valtier D, Miller JD, Guilleminault C, Dement WC. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci. 11:1991;2666-2671.
146. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Dement WC. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res. 733:1996;83-100.
147. 2receptors in the locus coeruleus. Brain Res. 500:1989;209-214.
148. Bowersox S, Kilduff T, Faul K, Dement WC, Ciaranello RD. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res. 402:1987;44-48.
149. Boehme R, Baker T, Mefford I, Barchas J, Dement WC, Ciaranello R. Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 34:1984;1825-1828.
150. Nissbrandt N, Engberg G, Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedeberg's Arch Pharmacol. 344:1991;16-28.
151. Kraczmar AG, Longo VG, De Carolis S. A pharmacological model of paradoxical sleep: the role of cholinergic and monoaminergic systems. Physiol Behav. 5:1970;175-182.
152. Reid MS, Siegel JN, Dement WC, Mignot E. Cholinergic mechanisms in canine narcolepsy: II. Acetylcholine release in the potine reticular formation is enhanced during cataplexy. Neuroscience. 59:1994;523-530.
153. Reid MS, Tafti M, Geary J, Nishino S, Siegel JM, Dement WC. Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation. Neuroscience. 59:1994;511-522.
154. Baghdoyan HA, Spotts JL, Snyder SG. Simultaneous pontine and basal forebrain microinjection of carbachol suppresses REM sleep. J Neurosci. 13:1993;229-242.
155. Rolls ET, Sanghera MK, Roper-Hall A. The latency of activation of neurones in the lateral hypothalamus and substantia innominata during feeding in the monkey. Brain Res. 1654:1979;121-135.
156. Reid M, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcokleptic canines. Exp Neurology. 151:1998;89-104.
157. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology. 39:1989;1505-1508.
158. Nishino S, Mao J, Sampathkumaran R, Honda K, Dement WC, Mignot E. Differential effects of dopaminergic and noradrenergic uptake inhibitors on EEG arousal and cataplexy of narcoleptic canines. Sleep Res. 25:1996;317.
159. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 17:1994;436-437.
160. Villablanca JR, Marcus RJ, Olmstead CE. Effects of caudate nuclei or frontal cortex ablations in cats. II. Sleep-wakefulness, EEG, and motor activity. Exper Neurol. 53:1976;31-50.
161. Kovacevic R, Radulovacki M. Manoamine changes in the brain of cats during slow-wave sleep. Science. 193:1976;1025-1027.
162. Jones BE. Basic mechanisms of sleep-wake states. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company. 1994;145-162.
163. Cirelli C, Pompeiano M, Tononi G. Neuronal gene expression in the waking state: a role for the locus coeruleus. Science. 274:1996;1211-1215.
164. Trulson ME. Simultaneous recording of substantia nigra neurons and voltametric release of dopamine in the caudate of behaving cats. Brain Res Bull. 15:1985;221-223.
165. Brown RM, Goldman PS. Catecholamines in neocortex of rhesus monkeys: regional distribution and ontogenetic development. rain Res. 142:1977;576-580.
166. Wiegand M, Moller AA, Lauer CJ, Stolz S, Schreiber W, Dose M. Nocturnal sleep in Huntington's disease. J Neurol. 238:1991;203-208.
167. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Neuroreport. 10:1999;3717-3724.
168. Okura M, Honda K, Riehl J, Mignot E, Nishino S. Roles of diencephalic dopaminergic cell groups in regulation of cataplexy in canine narcolepsy. Sleep. 22S:1999;S1.
169. Bagetta G, De Sarro G, Priolo E, Nistico G. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats. Br J Pharmacol. 95:1988;860-866.
170. Vogel G. Studies in psychophysiology of dreams III. The dream of narcolepsy. Arch Gen Psychiatry. 3:1960;421-428.
171. Nishino S, Riehl J, Hong J, Kwan M, Honda K, Mignot E. REM sleep, but not cataplexy, is controlled by a 30-minute normal ultradian rhythm in narcoleptic canines. Sleep. 1999;s2.
172. Okura M, Riehl J, Mignot E, Nishino S. Sulipride, D2/D3 antagonist, suppresses cataplexy, but has no effect on REM sleep in the canine narcolepsy model. Sleep Research Online. 2(S):1999;414.
173. Schneider VE, Ziegler B, Maxion H, Badawi M. Kurz- und Langzeiteffekte von Sulpirid auf das nachtschlaf-EEG des Menschen. Arzneim.-Forsch. 24:1974;990-993.